 | • レポートコード：MRC2106A154 • 出版社/出版日：Mordor Intelligence / 2021年5月25日 • レポート形態：英文、PDF、113ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査資料は、世界の単純ヘルペスウイルス治療市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、薬剤別（アシクロビル、バラシクロビル、ファムシクロビル、その他）分析、投与経路別（経口、注射、局所）分析、地域別分析、競争状況、市場機会/将来の見通しなどを徹底分析したものです。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の単純ヘルペスウイルス治療市場規模：薬剤別（アシクロビル、バラシクロビル、ファムシクロビル、その他） ・世界の単純ヘルペスウイルス治療市場規模：投与経路別（経口、注射、局所） ・世界の単純ヘルペスウイルス治療市場規模：地域別 ・競争状況 ・市場機会/将来の見通し |
The Herpes Simplex Virus Treatment Market is expected to register a CAGR of 5.9% during the forecast period owing to growing prevalence of simplex herpes virus. Herpes Simplex Virus is of two types, HSV-1 and HSV-2. According to the World Health Organization, in 2017, around 3.7 billion people globally, were diagnosed with HSV-1 aged under fifty. Moreover, HSV-2 occurred in 417 million people worldwide aged between 11 and 49. Hence, such higher prevalence of herpes simplex virus is expected to boost the market growth.
Key Market Trends
Acyclovir Segment is Expected to Hold a Significant Market Share in the Herpes Simplex Virus Treatment Market
– Acyclovir is a anti-viral therapy considered as the majorly used treatment in case of herpes, used against oral herpes and HSV encephalitis. It is purine nucleoside analog that enters into viral DNA to restrict it’s replication process by converting into acyclovir triphosphate. According to the study published in 2019, by Frontiers in Microbiology acyclovir when given in combination with omeprazole increased the anti-viral effects in HSV-1 and HSV-2 infection.
– Also, growing burden of HSV encephalitis is expected to boost the market in this particular segment. According to National Organizations for Rare Disorders, the incidence of acute encephalitis in the United States is around 2,000 cases per year and it constitutes for atleast 10% of total cases of encephalitis occurring in the United States.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to be dominant in genital herpes market owing to growing prevalence of infections of herpes simplex virus. According to American Sexual Health Association, approximately fifty percent of population in the United States suffers from oral herpes which is caused by HSV-1. Furthermore, around one in eight people is likely to suffer from HSV-2 infection. Moreover, according to the National Institutes of Health, by the age of 50 around 90% of people in the United States are exposed to this virus. Hence, this emerges the need for treatment of herpes and thereby expected to drive the herpes simplex virus treatment market.
Competitive Landscape
Some of the companies which are currently dominating the market are Teva Pharmaceuticals Inc., Apotex Inc., Mylan Pharmaceuticals Inc., Epi Health LLC, Zydus Pharmaceuticals, GlaxoSmithKline LLC, Carlsbad Tech, Avet Pharmaceuticals Inc., Glenmark Pharmaceuticals Inc. and Fresenius Kabi
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden Of Herpes Simplex Virus Infections Such As Genital Herpes
4.2.2 Increasing Research and Development Activities
4.3 Market Restraints
4.3.1 Social Stigma Associated with Sexually Transmitted Diseases Coupled with Rising Product Recalls
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Acyclovir
5.1.2 Valacyclovir
5.1.3 Famciclovir
5.1.4 Others
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Injection
5.2.3 Topical
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Rest of The World
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Teva Pharmaceuticals Inc.
6.1.2 Apotex Inc.
6.1.3 Mylan Pharmaceuticals Inc.
6.1.4 Epi Health LLC
6.1.5 Zydus Pharmaceuticals
6.1.6 GlaxoSmithKline LLC
6.1.7 Carlsbad Tech
6.1.8 Avet Pharmaceuticals Inc.
6.1.9 Glenmark Pharmaceuticals
6.1.10 Fresenius Kabi
7 MARKET OPPORTUNITIES AND FUTURE TRENDS